Fig. 2.

MLN0128 and TSA treatments enhance apoptosis in SKBR3 and MCF7 cells but not in MDA-MB-231 and MCF-10A cells. a SKBR3, b MCF7, c MDA-MB-231, and d MCF-10A cells were treated with MLN0128 (25 nM), TSA (100 nM), or Adriamycin (0.5 μg/mL) for 48 h. Whole cell lysates were collected and immunoblots were performed to detect cleaved PARP and a β-tubulin loading control. e MCF7 cells were treated with MLN0128 (25 nM) and/or TSA (100 nM) for 24 h. Annexin V was stained for and visualized by microscopy. The percentage of Annexin V-positive cells relative to total cells is expressed for four biological replicates. Error bars represent standard deviation. f MCF7 cells were treated with MLN0128 (25 nM) and/or TSA (100 nM) for 48 h. Cell cycle analysis was performed as described in materials and methods. Error bars represent the standard deviation from three biological replicates